Jazz Pharmaceuticals plc

NASDAQ:JAZZ

$121.59 USD

-$1.05 (-0.86%)

Volume
286.84K
Average Volume
714.08K
Market Capitalization
$7.35B
P/E Ratio
16.12
Dividend Yield
0.00%
Price Target
$194.00
Year High
$134.17
Year Low
$99.06
Payout Ratio
$0.24
Current Ratio
$4.26

Industry, Sector & symbol

Stock Exchange NASDAQ Global Select
CEO Mr. Bruce C. Cozadd
Industry Biotechnology
Sector Healthcare
Current Symbol JAZZ
CUSIP G50871105
CIK 0001232524
Web https://www.jazzpharma.com
Phone 353 1 634 7800
Currency USD
Employees 2800
Country IE

Liquidity

Debt-to-Equity Ratio 1.47
Payout Ratio 0.24
Current Ratio 4.26
Quick Ratio 3.74
Cash Ratio 2.15

Sales & Book Value

Annual Sales $3.83B
Price / Sales 1.84
Cash Flow 18.40
Price / Cash Flow 6.51
Price / Book 1.79

Price Target and Rating

Average Stock Price Forecast $194.00
High Stock Price Forecast $250.00
Low Stock Price Forecast $160.00
Forecast Upside/Downside -37.32%
Consensus Rating Buy
Rating Score(0-5) 4
Research Coverage 7 Analysts

Profitability

EPS (Most Recent Fiscal Year) $6.1
Trailing P/E Ratio 16.12
PEG Ratio 0.85
P/E Growth 0.85
Net Income $414.83M
Net Margin 11.60%
Pretax Margin 9.98%
Return on Equity 12.06%
Return on Assets 3.78%

Financials Score

AltmanZ Score 1.52
Piotroski Score 7.00
Working Capital 3.36B
Total Assets 12.26B
Ebit 799.35M
Market Cap 7.35B
Total Liabilities 8.08B

Poll Results

About Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with h ... epatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.

Wall Street Analysts Think Jazz (JAZZ) Could Surge 44.37%: Read This Before Placing a Bet

2024-11-29 10:57:20

The consensus price target hints at a 44.4% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer

2024-11-21 13:11:13

Following the FDA's approval, Jazz's Ziihera becomes the first dual HER2-targeted bispecific antibody and chemotherapy-free treatment approved for biliary tract cancer.

Jazz Pharmaceuticals receives FDA approval for biliary tract cancer treatment

2024-11-20 19:59:58

The U.S. Food and Drug Administration approved Jazz Pharmaceuticals' drug, zanidatamab-hrii, for the treatment of a type of biliary tract cancer, the company said on Wednesday.

Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

2024-11-20 19:19:00

Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2+ BTC in the U.S. Ziihera received accelerated approval based on results including a 52% objective response rate and median duration of response of 14.9 months as determined by independent central review (ICR) from the HERIZON-BTC-01 clinical trial Company to host investor webcast on Dec. 11, 2024 For U.S. media and investors only DUBLIN , Nov. 20, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) accelerated approval of Ziihera® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.1 Ziihera was approved under accelerated approval based on a 52% objective response rate (ORR) and a median duration of response (DOR) of 14.9 months as determined by independent central review (ICR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.1 The Phase 3 HERIZON-BTC-302 confirmatory trial is ongoing to evaluate zanidatamab in combination with standard-of-care therapy versus standard-of-care therapy alone in the first-line setting for patients with HER2-positive BTC.

Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference

2024-11-19 16:05:00

DUBLIN , Nov. 19, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2024 Global Healthcare Conference. Company management will participate in a fireside chat on Tuesday, December 3, 2024, at 7:15 a.m.

Frequently Asked Questions

What is the current Jazz Pharmaceuticals plc (JAZZ) stock price?

Jazz Pharmaceuticals plc(NASDAQ:JAZZ) stock price is $121.59 in the last trading session. During the trading session, JAZZ stock reached the peak price of $134.17 while $99.06 was the lowest point it dropped to. The percentage change in JAZZ stock occurred in the recent session was --0.86% while the dollar amount for the price change in JAZZ stock was -$-1.05.

JAZZ's industry and sector of operation?

The NASDAQ listed JAZZ is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of JAZZ?

Ms. Heidi Manna | Executive Vice President & Chief People Officer
Dr. Robert Iannone M.D. | Executive Vice President, Chief Medical Officer and Global Head of Research & Development
Mr. Bruce C. Cozadd | Co-Founder, Chairman & Chief Executive Officer
Dr. Jed Black M.D. | Senior Vice President of Sleep & CNS Medicine
Ms. Patricia Carr | Senior Vice President & Chief Accounting Officer

How many employees does JAZZ have?

Number of JAZZ employees currently stands at 2800. JAZZ operates from Waterloo Exchange, Dublin, None 4, IE.

Link for JAZZ official website?

Official Website of JAZZ is: https://www.jazzpharma.com

How do I contact JAZZ?

JAZZ could be contacted at phone #353 1 634 7800 and can also be accessed through its website. JAZZ operates from Waterloo Exchange, Dublin, None 4, IE.

How many shares of JAZZ are traded daily?

The average number of JAZZ shares traded daily for last 3 months was 714.08K.

What is the market cap of JAZZ currently?

The market value of JAZZ currently stands at $7.35B with its latest stock price at $121.59